Stockwinners Market Radar for September 03, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:33 EDT EastGroup Properties says operating portolio was 97.3% leased in August - Portfolio was also 96.5% occupied as of August 31st.

17:57 EDT Abbott's Bird sells over 6,000 common shares - In a regulatory filing, Abbott Laboratories senior VP Roger Bird disclosed the sale of 6,290 common shares of the company on September 1 at a price of $108.7328 per share.

17:25 EDT China Natural Resources regains Nasdaq compliance - China Natural Resources received written notice from Nasdaq that the company regained compliance with the minimum market value of listed securities requirement. The company had previously received a letter from Nasdaq on March 24 notifying the company that it was not in compliance with listing rules requiring listed securities to maintain a minimum MVLS of $35M.

17:19 EDT Guardant Health CFO sells 30.1K shares of common stock - In a regulatory filing, Guardant Health disclosed that its CFO Derek Bertocci sold 30.1K shares of common stock on September 1st in a total transaction size of $2.83M. The holding represents about 83% of his total owned.

17:16 EDT FDA approves additional doses of Eli Lilly's Trulicity in type 2 diabetes - The FDA today approved two additional doses of Eli Lilly's Trulicity, or dulaglutide. The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg in people with type 2 diabetes. The AWARD-11 trial evaluated the safety and efficacy of additional doses of Trulicity compared to Trulicity 1.5 mg, using two different statistical approaches. The efficacy estimand, which analyzes participants who remained on treatment throughout the trial, showed both doses led to significant reductions in A1C and weight. The additional doses of Trulicity will be available in United States pharmacies in late September.

17:08 EDT Sysco's Newcomb sells 10,000 common shares - In a regulatory filing, Sysco director Nancy Newcomb disclosed the sale of 10,000 common shares of the company on September 2 at a price of $60.38 per share.

17:05 EDT Kimberly-Clark to acquire Softex Indonesia for $1.2B in all-cash transaction - Kimberly-Clark announced that it has entered into a definitive agreement to acquire Softex Indonesia in an all-cash transaction for approximately $1.2B from a group of shareholders including CVC Capital Partners Asia Pacific IV. Since 1976, Softex Indonesia has built a successful personal care business with market positions and has consistently delivered double-digit growth. The company has manufacturing capabilities and a go-to-market distribution network. Softex Indonesia generated net sales of approximately $420M in 2019. Excluding one-time transaction and integration costs, the acquisition's impact on adjusted earnings per share in 2020 and 2021 is expected to be immaterial. The transaction will be financed primarily through incremental debt and secondarily cash on hand. The transaction is expected to close early in Q4 and is subject to customary closing conditions.

16:42 EDT Crowdstrike COO sells 25K shares of common stock - In a regulatory filing, Crowdstrike disclosed that its COO Colin Black sold 25K shares of common stock on September 1st in a total transaction size of $3.3M. The holding represents about 17% of his total owned.

16:33 EDT OraSure's ORAcollect RNA device included in EUA for MiraDx COVID-19 test - OraSure's ORAcollect RNA collection device was included along with other devices in the FDA Emergency Use Authorization granted to MiraDx, a Los Angeles-based molecular genetics company. This is the fifth EUA to include a collection device from the company's DNA Genotek subsidiary. MiraDx will utilize ORAcollect RNA to collect oropharyngeal samples in their COVID-19 testing program for essential workers and first responders. Samples are collected under the supervision of a healthcare professional. MiraDx is performing COVID-19 PCR-based viral detection testing in their laboratory that can provide 24-48 hour turnaround time.

16:31 EDT Bogota Savings Bank to merge with Gibraltar Bank - Bogota Financial Corp., the holding company for Bogota Savings Bank, and Gibraltar Bank announced the execution of a merger agreement pursuant to which Gibraltar will merge with and into Bogota. The merger is expected to increase Bogota Financial's consolidated assets from approximately $738.7M at June 30, 2020 to approximately $846M, and more than double its branch network. Gibraltar's existing three branch offices will become branch offices of Bogota. Following the merger, one director of Gibraltar will join the Board of Trustees of Bogota Financial, MHC, Bogota Financial's mutual holding company parent, and the Boards of Directors of Bogota Financial and Bogota Savings Bank. At the effective time of the merger, Robert Walsh, President and Chief Executive Officer of Gibraltar, will become the Executive Vice President and Chief Lending Officer of Bogota. Under the terms of the Merger Agreement, depositors of Gibraltar will become depositors of Bogota and will have the same rights and privileges in Bogota Financial, MHC, as if their accounts had been established in Bogota on the date established at Gibraltar. As part of the transaction, Bogota Financial will issue additional shares of its common stock to Bogota Financial, MHC in an amount equal to the fair value of Gibraltar as determined by an independent appraisal. These shares are expected to be issued immediately prior to completion of the merger. The transaction, which has been unanimously approved by the Boards of Directors of Gibraltar, Bogota Financial and Bogota, is expected to close in the first quarter of 2021. The transaction is subject to customary closing conditions, including the receipt of regulatory and Gibraltar member approvals.

16:27 EDT Innovative Industrial Properties exec chairman sells 15,000 common shares - In a regulatory filing, Innovative Industrial Properties executive chairman Alan D. Gold disclosed the sale of 15,000 common shares of the company on September 2 at a price of $125.5334 per share.

16:20 EDT Pitney Bowes announces pricing adjustments ahead of peak holiday shipping season - Pitney Bowes announced pricing adjustments for its domestic and cross-border delivery and returns services for the peak holiday shipping season. The pricing changes will be applied as flat, per-parcel adjustments, not to exceed $1.50 per parcel. The current expansion of e-commerce has created challenges as shipping costs are rising ahead of what is expected to be the largest online holiday shopping season in history. Major carriers have announced 2020 peak surcharges, many applied using opaque rules that make precise calculations difficult. This puts e-commerce merchants and shippers in the position of not being able to forecast growing costs during this most critical time of year. Alternatively, Pitney Bowes will present clients with a flat, per-parcel adjustment. Pitney Bowes will communicate the changes directly to clients. The timing and rate of adjustment will be based on each client's profile and portfolio of services. To help clients meet unprecedented demand, the company has expanded capacity, increased staffing, installed automated processing and sortation equipment, and strengthened its tracking and data infrastructure in time for peak season.

16:20 EDT American Outdoor Brands jumps 6.3% after Q1 earnings beat

16:17 EDT Gevo regains compliance with NASDAQ minimum bid price listing requirement - Gevo announced that it has received a letter from The NASDAQ Stock Market LLC notifying the company that it has regained compliance with the NASDAQ Capital Market's minimum bid price continued listing requirement. The letter noted that as of September 2, 2020, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for at least ten consecutive trading days. Accordingly, the company has regained compliance with NASDAQ Marketplace Rule 5550(a)(2) and NASDAQ considers the matter closed.

16:17 EDT Yext CEO says Q2 exceeded expectations - CEO Howard Lerman says: "We had a solid second quarter, exceeding the high end of our revenue and EPS guidance, while also driving sales efficiencies. Our new 'Land with Answers' sales motion is the difference maker, and we have new logos using Yext to power their site search every day. And when we put our Official Answers Engine on a customer's website, we are delivering on our mission to help every business and organization around the world deliver official answers every time people search."

16:12 EDT Relay Therapeutics announces first patient dosed in RLY-4008 trial - Relay Therapeutics announced the first patient has been dosed in a first-in-human clinical trial of RLY-4008 enriched for patients with intrahepatic cholangiocarcinoma, or ICC, and other advanced solid tumors harboring a fibroblast growth factor receptor 2, or FGFR2, alteration. RLY-4008 is the only selective small molecule inhibitor of FGFR2 in clinical development.

16:11 EDT Organovo regains compliance with Nasdaq - Organovo announced that it has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. On September 2, Organovo received a letter from the listing qualifications department of Nasdaq stating that because Organovo's common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, Organovo had regained compliance with the minimum bid price requirement and that Nasdaq had closed the matter.

16:07 EDT Tilly's reports August revenue $50.2M, down 35.6% - The Company's total net sales for fiscal August ended August 29, 2020, were $50.2 million, a decrease of $27.7 million or 35.6%, compared to $77.9 million for fiscal August last year. Net sales from physical stores, including all periods of store closures and net sales from new stores not yet open for a full year, were $36.6 million, a decrease of $31.6 million or 46.3% compared to $68.3 million for the comparable period last year. Net sales from e-commerce were $13.6 million, an increase of $4.0 million or 40.6% compared to $9.6 million for the comparable period last year. Net sales during the fiscal month of August have represented approximately 50% of third quarter net sales for each of the past four fiscal years. However, in many school districts across the country this year, there have been significant delays in back-to-school dates and adjustments of some or all of their curriculum to an online or remote format. The first two weeks of fiscal August last year were the two highest net sales volume weeks of the third quarter, during which the Company generated net sales of $49.1 million last year in a normal, healthy back-to-school season compared to $27.0 million for the same two weeks this year. This led to a highly negative start to the third quarter of fiscal 2020 in terms of comparable net sales for the Company. Although comparable net sales remained highly negative for the rest of the month compared to last year, results improved trend-wise from week to week as the month progressed.

16:05 EDT Golub Capital CEO acquires nearly 85,000 common shares - In a regulatory filing, Golub Capital BDC CEO David Golub disclosed the purchase of 84,792 common shares of the company on September 2 at a price of $13.2931 per share.

16:04 EDT Fabrinet's Toh-Seng Ng sells 11,000 ordinary shares - In a regulatory filing, Fabrinet EVP of Special Projects Toh-Seng Ng disclosed the sale of 11,000 ordinary shares of the company on September 1 at a price of $67.859 per shrae.

16:02 EDT Mondelez to require traceable, forest-monitored palm oil in 2021 - Mondelez International announced significant progress in advancing requirements for traceable, forest-monitored palm oil and confirms strong progress against sustainable sourcing goals. The new requirements include traceability to plantation and satellite monitoring covering all palm oil concessions* supplying mills attributed to the company, against the deforestation criteria set out in its Palm Oil Action Plan. All mills must be identified on Global Forest Watch, with no active grievances against concessions in their direct supply, or operated by the same producer groups elsewhere. In addition, suppliers must have third-party assurance of their monitoring process and systems used and be subject to cross-check by Mondelez International.

16:02 EDT First National Bank to acquire branch location from Bangor Savings Bank - First National Bank, a subsidiary of The First Bancorp, Inc., and Bangor Savings Bank, a subsidiary of Bangor Bancorp, MHC, jointly announced that the two banks have signed a definitive agreement for First National Bank to purchase a bank branch located at 1 Belmont Avenue in Belfast, Maine. As part of the transaction, First National Bank will acquire deposit accounts totaling approximately $16.5M as of August 31, 2020, as well as $23.5M in loan balances. The 1 Belmont Avenue branch in Belfast is one of six locations to be acquired by Bangor Savings Bank through its pending merger with Damariscotta Bankshares, Inc., parent of Damariscotta Bank & Trust Company. Bangor Savings Bank and DB&T will work with First National Bank to ensure as seamless a transition as possible for the Belfast customers of DB&T. Customers of the existing Bangor Savings Branches in Belfast, located at 7 Belmont Plaza and 106 Main Street, will not be impacted. The final value of the transaction is estimated to be $24.8M, which includes the loans, an assignment of a ground lease, leasehold improvements, and furniture and equipment for the Belfast location, plus the premium paid for the deposits. The transaction is subject to regulatory approval and is expected to close in the fourth quarter of 2020 after completion of the pending DB&T acquisition.

14:55 EDT Cognex's Parrotte sells 12,700 common shares - In a regulatory filing, Cognex director Dianne M. Parrotte disclosed the sale of 12,700 common shares of the company on September 1 at a price of $69.557 per share.

14:31 EDT Capstone Turbine secures FPP long-term service contract in biogas plant - Capstone Turbine today that IBT Connecting Energies GmbH, Capstone's exclusive distributor for Italy, signed a new factory protection plan, or FPP, long-term service contract for a Capstone C600 Signature Series microturbine installed in a biogas purification plant. The C600S microturbine runs grid-connected, using digester gas as a fuel source. This innovative application uses the microturbine exhaust to pre-heat the digester while selling the electricity produced to the grid and reducing flared gas emissions.

14:02 EDT Ball Corp.'s Baker sells over 23,000 common shares - In a regulatory filing, Ball Corp. VP, general counsel, and corporate secretary Charles E. Baker disclosed the sale of 23,146 common shares of the company on September 2 at a price of $81.9052 per share.

13:29 EDT J&J says COVID vaccine candidate prevents severe disease in pre-clinical studies - Janssen's lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people, Johnson & Johnson announced. The data, published today in Nature Medicine, demonstrated that the company's investigational adenovirus serotype 26 vector-based vaccine elicited an immune response as demonstrated by "neutralizing antibodies" and prevented severe clinical disease - including weight loss, pneumonia and mortality - in Syrian golden hamsters upon challenge. This publication follows Johnson & Johnson's recent announcement that its vaccine candidate elicited an immune response in a pre-clinical study in non-human primates, that correlated with protection against SARS-CoV-2, providing complete protection against viral replication in the lungs. The latest research tested the vaccine candidate in Syrian golden hamsters, as they are more susceptible to clinical disease than NHPs, which typically do not get severe disease. "This pre-clinical study further validates our confidence in our SARS-CoV-2 vaccine candidate. With our Phase 3 trials planned to start this month, we remain committed to expanding our manufacturing and distribution capabilities to enable global access to our SARS-CoV-2 vaccine candidate should it prove to be safe and effective in humans," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. Reference Link

13:20 EDT Ackman says has not sold 'a share' of Hilton - Bill Ackman, the CEO of Pershing Square Capital Management, continues to be interviewed on Bloomberg television.

13:07 EDT Verizon boosts quarterly dividend to 62.75c from 61.50c - Verizon Communications declared a quarterly dividend of 62.75c per outstanding share, an increase of 1.25c per share from the previous quarter. The quarterly dividend is payable on November 2, to shareholders of record at the close of business on October 9. This is the 14th consecutive year Verizon's board has approved a quarterly dividend increase, the company noted.

12:48 EDT DIU selects Google Cloud to aid U.S. military with predictive cancer diagnoses - Google Cloud announced that the Defense Innovation Unit, DIU, has chosen Google Cloud to prototype an AI-enabled digital pathology solution at select DoD facilities. The project includes the delivery of augmented reality microscopes to DoD's medical facilities and access to artificial intelligence, AI,models that can help military doctors with cancer detection tasks on multiple disease areas. The early access to the digital pathology platform is for research use only. DIU is the organization exclusively focused within the Department of Defense, DoD, on scaling commercial technology across the DoD. The Veterans Affairs Center for Innovations in Quality, Effectiveness, and Safety recently reported that within the United States, an estimated 5% of outpatient diagnoses are conducted in error. This translates to misdiagnosis of 12M patients each year.* At the same time, the Defense Health Agency spends approximately $1.7B of its annual budget on cancer research, and that figure continues to grow. The goal of the DIU-Google Cloud project is to help improve the accuracy of diagnoses, assisting physicians who face an overwhelming volume of data when making diagnostic and treatment decisions--and to help lower overall healthcare costs. Working with DIU, Google Cloud will prototype the delivery of an augmented reality microscope that overlays AI-based information for doctors, providing pathology-based cancer detection tools at the point-of-care. Google's approach will leverage TensorFlow, an open-source framework to help deliver machine-learning models as well as the Google Cloud Healthcare API for data ingestion and de-identification to maximize patient privacy. Reference Link

12:34 EDT Amazon debuts Alexa for Residential for property managers and apartments - In a blog posting Amazon said: Alexa for Residential allows residential buildings and communities to deploy and manage Alexa-enabled devices and experiences with the help of solution providers. "With Alexa, residents can have voice-enabled smart home experiences from the moment they move in, with zero setup," noted Amazon. "Make your property more attractive to residents. Integrate Alexa and make smart home devices easier to use for your residents. It is a one-time investment, one-time setup, with years of benefits. Alexa-enabled devices will be fixtures in the unit just like other home appliances. New residents will find Alexa-enabled devices ready to control their lights, thermostat, lock, blinds, and more with no setup required," added Amazon in its statement. Reference Link

12:10 EDT Amazon to create 10,000 new permanent jobs across U.K. this year - Amazon announced that 10,000 new permanent roles are being created across the U.K. in 2020, taking the company's total permanent U.K. workforce to more than 40,000. Amazon has already added 3,000 new permanent roles to its workforce across its UK network of fulfilment centres, sort centres and delivery stations - including at a new hi-tech fulfilment centre in the North East of England which opened in May. The company will add a further 7,000 new permanent roles by the end of 2020 across more than 50 sites, including Corporate offices and two new fulfilment centres launching in the autumn in the North East and in the Midlands. The new roles, including engineers, graduates, HR and IT professionals, health and safety and finance specialists, as well as the teams who will pick, pack and ship customer orders, will help Amazon meet growing customer demand and enable small and medium sized enterprises selling on Amazon to scale their businesses. Amazon has already offered temporary roles to thousands of people whose job was impacted at the height of the Covid-19 pandemic, many of whom will now be able to transition into a permanent role with the potential for a career within Amazon. In addition, Amazon is creating more than 20,000 seasonal positions across the U.K. ahead of the festive period at its sites across England, Scotland, Wales and Northern Ireland and at three pop-up fulfilment centres.

12:00 EDT Ciena falls -26.2% - Ciena is down -26.2%, or -$15.73 to $44.34.

12:00 EDT Whiting Petroleum rises 8.3% - Whiting Petroleum is up 8.3%, or $1.62 to $21.12.

12:00 EDT Garrett Motion rises 23.9% - Garrett Motion is up 23.9%, or 65c to $3.35.

11:48 EDT Nintendo unveils 'Super Mario 3D All-Stars,' 'Mario Kart Live' - In a Nintendo Direct this morning, Nintendo unveiled a number of new Mario-related products in honor of the 35th anniversary of the release of the original "Super Mario Bros." Nintendo detailed several games, products and in-game events that are all arriving for the 35th anniversary of "Super Mario Bros." This includes games new to the Nintendo Switch family of systems like "Super Mario 3D All-Stars," a collection of three Super Mario games of the modern era, "Super Mario 64," "Super Mario Sunshine" and "Super Mario Galaxy"; "Super Mario Bros. 35," a 35-player online battle in the world of the original "Super Mario Bros." game; and "Super Mario 3D World + Bowser's Fury," an enhanced version of the "Super Mario 3D World" game which originally launched on Wii U. Additionally, the video revealed other Super Mario experiences launching this year, like "Mario Kart Live: Home Circuit," which brings the fun of the Mario Kart series to the real world using the Nintendo Switch system to control a real-life, physical Kart; the launch of the classic Super NES game "Super Mario All-Stars" on Nintendo Switch Online; and a new Nintendo product called Game & Watch: Super Mario Bros., a mini gaming device inspired by the retro Game & Watch systems that plays the original Super Mario Bros., Super Mario Bros.: The Lost Levels and Ball games. "Super Mario 3D All-Stars" will launch for the Nintendo Switch on September 18 and will be available until about March 31, 2021, while "Super Mario 3D World + Bowser's Fury" launches on Switch on February 12, 2021. In addition, "Mario Kart Live" launches on October 16 at a suggested retail price of $99.99. Reference Link

11:37 EDT Square investigating reports that logins are down currently - Square said in a report posted to its corporate status page: "We are receiving reports that logins are down currently. We are in the process of updating issquareup.com with relevant and up to date information. Please reference this page for new updates. Thanks for your patience!" Reference Link

11:11 EDT U.S. Army awards Ameresco, Duke Energy UESC contract for Fort Bragg - Ameresco (AMRC) announced that the U.S. Army has awarded to Duke Energy (DUK) and Ameresco's Federal Solutions Group a utility energy service contract to implement power generation and facility efficiency improvements at Fort Bragg. In partnership with Duke Energy, Ameresco will deploy a 1.1 megawatt floating solar photovoltaic system on the Big Muddy Lake at Camp Mackall, a remote Special Forces training site at the base. A 2 MW battery energy storage system will provide seamless transition to on-site generation during utility provider outages. This system will supplement power from the local grid and provide backup power during electric service outages. Under the $36M design-build contract, Duke secures third-party financing to fund construction, and the U.S. Army pays down the financing annually with the utility savings that the project generates over the term of the contract. Ameresco will also implement improvements to the boiler system, HVAC systems and lighting systems, as well as water conservation systems. In year one of the performance period, the contract will result in utility cost savings for the Army of over $2M, a reduction in site energy use of 7% and a site water use reduction of 20%. In addition to reducing facility energy consumption, the modernization of these building systems is designed to reduce the number and frequency of equipment failures, freeing Fort Bragg personnel to focus on mission-critical activities. Construction is slated to begin in November 2020.

10:40 EDT Akumin commences trading on Nasdaq, to delist U.S. dollar listing on TSX - Akumin announced that its common shares have been approved for listing and trading in U.S. dollar currency on the Nasdaq Capital Market, with trading on the NASDAQ commencing at the start of trading on September 3, under the symbol "AKU". In connection therewith, the corporation intends to voluntary delist its "AKU.U" U.S. dollar listing on the Toronto Stock Exchange. It is expected the delisting will be effective after markets close on September 8. Akumin's common shares will continue to be traded on the TSX in Canadian dollar currency under the symbol "AKU". Akumin will also continue to report its financial statements in U.S. dollars. Riadh Zine, President and CEO of Akumin, said, "Our NASDAQ listing is a significant milestone in the history of our company. It marks the beginning of the execution of our U.S. capital markets strategy, which we expect will have many benefits including broadening our investor base."

10:21 EDT Amarin loses Court of Appeals bid to revive Vascepa patent case - The U.S. Court of Appeals for the Federal Circuit in Washington affirmed a trial court ruling that invalidated six of Amarin's patents on its Vascepa heart treatment. The decision comes one day after the court heard arguments in the case. Shares of Amarin are down 14c to $4.90 in early trading.

10:19 EDT Hikma reports 'favorable court ruling' for generic Vascepa - Hikma Pharmaceuticals (HKMPF) announces that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Nevada finding that Hikma's generic version of Vascepa 1gm does not infringe any valid claim of six key Amarin-owned patents. Hikma received FDA approval for the product in May 2020 and is working towards a launch. "We are very pleased with the Federal Circuit's swift decision and to be one step closer to launching a generic version of this important medicine for US patients and healthcare providers, helping us to continue putting better health, within reach, every day," said Brian Hoffmann, President of Hikma Generics. "Today's decision demonstrates Hikma's ability to successfully challenge patents on important medicines and to provide value to our customers and millions of patients across the United States." Amarin (AMRN) is the company that markets branded Vascepa.

10:05 EDT General Dynamics, Dedrone enter partnership for counter-drone technology - General Dynamics Missions Systems and Dedrone announced their strategic counter-drone partnership, providing General Dynamics' global network with access to Dedrone's complete drone detection and defeat technology. As part of this strategic agreement, General Dynamics Mission Systems becomes a value-added reseller for Dedrone's counter-unmanned aerial system capabilities and has made a significant equity investment in Dedrone. General Dynamics will exclusively supply Dedrone's counter-drone technology to their global defense, civil government, intelligence, and critical infrastructure customers. In the counter-drone technology market, Dedrone's exclusive focus on C-UAS detection and defeat have enabled them to become the industry leader with the rare distinction of having production systems fielded and in operational use worldwide. The Dedrone C-UAS technology portfolio combines machine-learning software with best-in-class hardware sensors, electronic attack methods such as smart jamming, and defeat weapons to provide early warning, classification of, and mitigation against drone threats. Dedrone's capabilities are used by hundreds of customers globally, including the U.S. military, allied and coalition forces, correctional facilities, airports, utilities, and corporations, as well as other public and private organizations.

10:00 EDT PagerDuty falls -26.0% - PagerDuty is down -26.0%, or -$9.08 to $25.91.

10:00 EDT Zuora falls -27.0% - Zuora is down -27.0%, or -$4.37 to $11.80.

10:00 EDT Norwegian Cruise Line rises 9.4% - Norwegian Cruise Line is up 9.4%, or $1.59 to $18.58.

09:47 EDT PagerDuty falls -22.5% - PagerDuty is down -22.5%, or -$7.87 to $27.12.

09:47 EDT Zuora falls -26.7% - Zuora is down -26.7%, or -$4.32 to $11.85.

09:47 EDT Carnival rises 8.1% - Carnival is up 8.1%, or $1.36 to $18.07.

09:31 EDT QuantumScape to list on NYSE through merger with Kensington Capital Acquisition - QuantumScape (QS) and Kensington Capital Acquisition (KCAC) announced a definitive agreement for a business combination that would result in QuantumScape becoming a publicly listed company. The companies said in a release, "Upon closing of the transaction, the combined company will be named QuantumScape and is expected to remain listed on the NYSE and trade under the new ticker symbol 'QS.' The business combination values QuantumScape at an implied $3.3B pro forma enterprise value. The boards of both Kensington and QuantumScape have approved the proposed transaction, which is expected to be completed in Q4, subject to, among other things, the approval by Kensington's stockholders and satisfaction or waiver of the other conditions stated in the definitive documentation."

09:26 EDT SuperCom announces PureSecurity contract in Caribbean - SuperCom said in a release, "SuperCom announced, in the midst of new product launches and strong international interest in the Company's human tracking technology, the signing of a new contract in the Caribbean region. The related pilot for this opportunity was recently announced on July 10. SuperCom's technology was selected for its ability to ensure public safety by securely monitor offender location restrictions while also providing a platform to create tools that aid in the reduction offender recidivism."

09:24 EDT Campbell Soup says encouraged by retention of new customers - Says FY20 was separated into two distinct halves. Says very focused on household penetration. Says making every effort to retain the new households and younger consumers. Says remains very encouraged by the retention of these new consumers. Says increased household penetration across most key brands. Says total household penetration remained up four points for the company versus a year ago. Says total soup sales growth was remarkable. Says broth is an important area that it is continuing to focus on. Says extremely pleased with significant gains in household penetration, while volume per buyers remained elevated even in the summer. Says shelf and packaging is a bit behind as the company has prioritized supply and keeping shelves full in the COVID-19 environment. Comments taken from Q4 earnings conference call and investor presentation slides.

09:23 EDT Designer Brands ended Q2 with inventory down 37% vs. last year - Comments taken from Q2 earnings conference call.

09:20 EDT MTBC offers Health Records on iPhone through talkEHR platform - MTBC announced it is offering Health Records on iPhone through its talkEHR platform. Health Records brings together hospitals, clinics, and the existing Apple Health app to make it easy for patients to see their available medical data, from multiple providers, whenever they choose. The Health Records feature is part of the Health app, which also shows activity, heart rate, nutrition, and other health data consolidated from iPhone, Apple Watch and HealthKit-enabled third-party apps. Health Records is available for iPhone users running iOS 11.3 or higher. talkEHR is a cloud-based electronic health record, medical billing, and telehealth software platform that streamlines clinical and financial workflows for medical practices. Patients can stay connected to their healthcare provider through talkEHR's Personal Health Record app and, now with the power of Health Records for iPhone, can aggregate their health records on their iPhone for a more holistic view of their health. MTBC is dedicated to helping providers enhance the patient experience, and supporting Health Records on iPhone gives providers the ability to give their patients even greater access to their data.

09:18 EDT Bridgeline Digital's Celebros Search selected by pharmacy group in Ireland - Bridgeline Digital announced that an independent pharmacy group in Ireland has selected its Celebros Search solution to power its eCommerce website.

09:18 EDT Verizon pilots Quantum Key Distribution to protect data - Verizon recently conducted a trial in the Washington D.C. area deploying a Quantum Key Distribution network. The successful trial positions Verizon as one of the first carriers to pilot QKD in the U.S. In the recent trial, live video was captured outside of three Verizon locations in the D.C. area, including the Washington DC Executive Briefing Center, the 5G Lab in D.C and Verizon's Ashburn, VA office. Using a QKD network, quantum keys were created and exchanged over a fiber network between Verizon locations. In the trial, video streams are encrypted and delivered more securely allowing the recipient to see the video in real-time while ensuring hackers are instantly detected. A QKD network derives cryptographic keys using the quantum properties of photons to prevent against eavesdropping. Verizon also demonstrated that data can be further secured with keys generated using a Quantum Random Number Generator that creates truly random numbers that can't be predicted. With QKD, encryption keys are continuously generated and are immune to attacks because any disruption to the channel breaks the quantum state of photons signaling eavesdroppers are present.

09:16 EDT Verizon advances 5G network, cybersecurity - Verizon's Network Security engineers recently engaged in a series of successful trials to future-proof its 5G network against security threats and advance security measures to protect the confidentiality, integrity and availability of Verizon's 5G network. Verizon engineers are continuing to drive innovation and leadership in the area of cyber security, knowing that threats evolve nearly as quickly as new technology is introduced. To that end, Verizon engineers and partners are advancing the following initiatives: Security Network Accelerators to improve latency and operational efficiency: As network operations become more complex, additional purpose-built hardware supporting security functions such as firewalls, IDS, DDoS, Probes and Packet brokers are deployed throughout the network. The addition of this hardware introduces additional latency and opens the door for greater maintenance as well as additional points of vulnerability. To solve for this, Verizon engineers have virtualized many of these functions and moved them to the cloud. However, for higher performance security functions, however, Verizon engineers are working to install programmable network accelerators as a way to mesh together multiple high performance, latency dependent security functions into a single, AI ML driven Network Accelerator, reducing operational expenses, reducing reliance on programming by people and increasing the efficiency of delivering these security functions. Verizon is working with the University of California Santa Barbara to develop AI ML driven firewall and IDS capabilities that are able to be delivered in a whitebox network accelerator. AI/ML Security: AI/ML is a technology that is being broadly adopted in all industries, including 5G, to automate decision making, troubleshooting, forecasting, network management, security, and more. With the acceleration in use of AI ML throughout networks, Verizon engineers are developing an AI ML Security Framework which will offer additional protection in the AI ML models that power the network. This AI ML Security Framework will help verify the providence of information being fed into AI ML algorithms, ensure the AI ML models are operating correctly, and will manage the security around where that information goes and how it is interpreted and used. Verizon engineers are trialing the framework in two AI ML use cases at present; one to detect security anomalies in the network and the other to analyze MIMO antenna performance at cell tower. Machine State Integrity: Understanding the criticality of both the confidentiality and integrity of data, Verizon is working with Guardtime and WWT to provide near real-time, non-repudiated evidence of tampering in a machine's state while also providing meaningful reductions in time between a machine's compromise and its detection. If a security breech or incident occurs, it is critical to be able to quickly identify changes in data. With the amount of data stored in systems today, identifying breeches in data integrity can be a time consuming and onerous task. Verizon engineers and our vendors are using cryptographically secure functions to create digital fingerprints of data and store them in a blockchain so they cannot be modified. These fingerprints are fully secure, unhackable and accessible anywhere in the world. By comparing fingerprints stored in the blockchain to fingerprints taken during or after a cyber attack, companies can more quickly and easily determine if the integrity of their data was compromised. Verizon, Guardtime and WWT are preparing for trials of this new technology to begin. When complete, Verizon engineers will be able to leverage machine state integrity to more effectively protect the data on the Verizon network including configuration of towers, Verizon Cloud servers and more. Secure Credentialing Management System for Connected Vehicles: Connected vehicles need to connect to each other, to roadside infrastructure, to other road users and to cloud-based services. SCMS is the fundamental mechanism to ensure those connections are protected against attacks on integrity, confidentiality, and repudiation. The SCMS provides digitally signed certificates and activation codes that are used to validate vehicle safety messages. For the first time in the Connected Vehicle industry, a joint Verizon and LG team effort validated and secured CV2X Basic Safety Messages using a standards-compliant SCMS hosted on a Verizon 5G MEC. This milestone was completed at the Mcity Test Track in Ann Arbor, MI and validates Verizon's core capabilities in 5G network connectivity. It also demonstrates how 5G MEC can be leveraged for public safety and Connected Vehicle security.

09:15 EDT Del Taco, Beyond Meat announce promotion through DoorDash - Del Taco (TACO) announced a new partnership with Beyond Meat (BYND) and DoorDash. Starting September 4, through September 7, customers can use the DoorDash app to receive free delivery on all orders that include any Epic Burrito with Beyond Meat.

09:13 EDT Aditx Therapeutics signs collaboration agreement with Salveo Diagnostics - Aditx Therapeutics announced that it has signed a Collaboration Agreement with Salveo Diagnostics, a CLIA and CAP Accredited laboratory company focused on end-to-end personalized medicine solutions aimed at preventing, stopping, and reversing the epidemic of chronic disease. Aditxt believes that the collaboration provides it with access to a regulatory path, operational foundation and sales channels that will enable the Company to accelerate the launch of theAditxtScore platform. Aditxt will be seeking to utilize Salveo's facilities and capabilities as a launching pad for commercializing AditxtScore starting in Q4, 2020. As previously announced, Aditxt submitted an Emergency Use Authorization application with the U.S. Food and Drug Administration for AditxtScore for COVID-19, for use in detecting antibodies against SARS-CoV-2 antigens.

09:12 EDT INmune Bio announces issuance of patent covering INKmune therapy - INmune Bio announced that the United States Patent & Trademark Office has issued US Pat. No. 10,758,567 B2, titled "IN VIVO PRIMING OF NATURAL KILLER CELLS," which covers a method for treating cancer using INKmune, a natural killer cell priming technology. The patent expires in 2036.

09:12 EDT Tesla down 7% day after Baillie Gifford trims stake due to rise in shares - Shares of Tesla are down 7% to $416.02 in pre-market trading after U.K. fund manager Baillie Gifford disclosed in a regulatory filing yesterday morning that it has reduced its stake in the electric carmaker to 4.25%. The investment company said the recent rise in Tesla's share price meant it needed to reduce its holding due to guidelines restricting the weight of a single stock in client portfolios. However, James Anderson, co-manager of Baillie Gifford's flagship Scottish Mortgage Investment Trust PLC, said "we intend to remain significant shareholders for many years ahead. We remain very optimistic about the future of the company," according to Dow Jones. "Tesla no longer faces any difficulty in raising capital at scale from outside sources but should there be serious setbacks in the share price, we would welcome the opportunity to once again increase our shareholding," Anderson reportedly added.

09:11 EDT Avalon GloboCare announces mesenchymal stromal cell therapeutic platform - Avalon GloboCare announced the launch of its new allogeneic mesenchymal stromal cell therapeutic platform. Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2, and for bone marrow transplant related complications of acute graft versus host disease. Mesenchymal stromal cells are typically isolated from the bone marrow, umbilical cord blood, fat tissue and other tissue types. MSCs possess unique qualities including anti-inflammatory and immunomodulatory activities. MSCs have multiple functions within the immune system, affecting many different immune cell types. MSCs have the ability to suppress T-cell proliferation, cytokine secretion and regulate the balance of antibody-based and cell-based immune responses. MSCs are capable of inhibiting the activation of dendritic cells and blocking the ability of dendritic cells to present antigens to other cells in the immune system. MSCs can also tone down the abnormal release of either antibodies from B-cells or cytokines from natural killer cells. Avalon's MSC therapeutic platform represents the culmination of extensive research and development that leverages the Company's scientific and clinical expertise in cellular therapy and stem cell-derived exosome applications. Avalon believes that this allogeneic MSC platform could offer a unique and efficacious approach to treat the potentially fatal acute respiratory distress syndrome, multi-system inflammatory syndrome and cytokine storm related to severe cases of COVID-19. Accumulating evidence has revealed that aberrant and excessive immune responses evoked by a SARS-CoV-2 virus infection are involved in lung damage and multi-organ injury seen in some patients with moderate and severe COVID-19. Also involving an excessive immune assault on multiple organs and tissues, including the gut, liver and skin, aGVHD is a medical complication that is potentially life-threatening and commonly seen in allogeneic bone marrow transplantation. There are currently no effective therapies for the prevention and treatment of aGVHD. The Company is currently progressing its planned pre-clinical testing for its MSC therapeutic platform for COVID-19 and aGVHD, with plans to initiate a first-in-human clinical study during the first half of 2021, assuming clearance from U.S. and/or non-U.S. regulatory agencies.

09:09 EDT Okta appoints Alvina Antar as chief information officer - Okta (OKTA) announced the appointment of Alvina Antar as senior VP, chief information officer. Antar brings more than 20 years experience at IT organizations at both Fortune 50 companies and startups. At Okta, Antar will report directly to Hector Aguilar, Okta's president of technology, and will be responsible for enabling experiences for Okta customers and employees. As Zuora's (ZUO) first CIO, Antar built the company's IT department into a modern-day business technology organization, led through a successful IPO in 2018 and saw the company's revenue grow from $30M to $300M.

09:08 EDT Tonix Pharmaceuticals initiates enrollment in RALLY study of TNX-102 SL - Tonix Pharmaceuticals announced that the first participant was enrolled in the Phase 3 RALLY study of TNX-102 SL 5.6 mg for the management of fibromyalgia. RALLY is the Company's second of two potentially pivotal Phase 3 studies of TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine HCl taken daily at bedtime for the management of fibromyalgia. Both of the current Phase 3 trials are studying TNX-102 SL at a dose of 5.6 mg which is twice the 2.8 mg dose used in the Company's prior Phase 2 and 3 studies in fibromyalgia. Tolerability of the higher dose was documented in an earlier Phase 3 trial of TNX-102 SL in posttraumatic stress disorder. Both of the current Phase 3 fibromyalgia studies are being conducted using essentially the same protocol. An interim analysis of the first of the current fibromyalgia trials, RELIEF, is expected by the end of September, with topline results expected by year end. If the RALLY study maintains current enrollment timelines and objectives, it is expected to report topline data in the second half of next year. Positive outcomes in both studies may potentially put Tonix in a position to file a New Drug Application with the FDA for marketing approval in the second half of 2022.

09:07 EDT Just Energy receives final court approval to proceed with recapitalization - Just Energy Group announced that it has received the final court approval required to close the Company's recapitalization plan and subscriptions totaling approximately C$52 million through the equity subscription option included in its Recapitalization, with the remaining approximately C$48 million to be provided by the backstop parties. The Recapitalization is being implemented by way of a plan of arrangement and earlier today, Just Energy obtained the final order from the Ontario Superior Court of Justice enabling the Plan of Arrangement to proceed. The Company expects the Plan of Arrangement to close on or about September 16, 2020, pending receipt of regulatory approvals. The Recapitalization is part of a comprehensive plan to strengthen and de-risk the business and position Just Energy for sustainable growth as an independent industry leader. The Recapitalization significantly improves Just Energy's financial flexibility with a cash injection from its equity raise and reduces net debt and preferred shares by approximately C$520 million. As part of the Recapitalization Plan, holders of Just Energy's existing Term Loan, Eurobond, Subordinated Convertible Debentures, Preferred Shares and common shares as of July 23, 2020 were entitled to subscribe for common shares at a price per share of C$3.412. The equity subscription option received interest from all security classes, with subscriptions totaling 15,174,950 common shares which will result in cash proceeds for Just Energy of approximately C$52 million. Pursuant to the previously announced backstop commitments, the backstop parties have agreed to acquire the remaining common shares not subscribed for by eligible holders under the equity subscription option, totalling 14,137,580 common shares, on a post-consolidation basis. The aggregate proceeds from the equity subscription option are C$100 million and will be used to reduce debt and for general corporate purposes. Following completion of the Recapitalization, the principal shareholder of the Company will be a group of related investment entities comprised of OCII LVS XIV LP, LVS III SPE XV LP, HVS XVI LLC and TOCU XVII LLC that will collectively beneficially own 13,872,207 common shares of Just Energy, representing approximately 29% of the issued and outstanding common shares. Of this amount, OCII LVS XIV LP will hold 8,323,327 common shares, representing approximately 17% of the issued and outstanding common shares. The foregoing common shares will be acquired pursuant to the Recapitalization, including as a result of the backstop commitments provided by such investment entities. Such investment entities are also lenders to the Company pursuant to an amended and restated term loan debt agreement that was entered into in conjunction with the Recapitalization. The Company confirms today that the previously announced consolidation of its common shares on a 33 to 1 basis is anticipated to be effective on or about September 16, 2020. The common shares will begin trading on the New York Stock Exchange and the Toronto Stock Exchange on a post-Consolidation basis at the opening of trading on September 17, 2020. Just Energy further confirms today that its previously announced exchange of all outstanding 8.50% series A fixed-to-floating rate cumulative redeemable perpet, is anticipated to be effective on or about September 16, 2020. Upon completion of the Preferred Share Exchange, the Preferred Shares will be delisted from the NYSE and the TSX and the delisting will be effective before or at the opening of trading on September 17, 2020. Just Energy further confirms today that its previously announced exchange of all outstanding $100 million 6.75% convertible unsecured senior subordinated debentures due March 31, 2023 and $160 million 6.75% convertible unsecured senior subordinated debentures due December 31, 2021 into new common shares, on the basis of 35.920689 new common shares for every $1,000 principal amount of Subordinated Convertible Debentures, is anticipated to be effective on or about September 16, 2020. Upon completion of the Convertible Debenture Exchange, the Subordinated Convertible Debentures will be delisted from the TSX and the delisting will be effective before or at the opening of trading on September 17, 2020. No fractional common shares will be issued in connection with the Consolidation, the Preferred Share Exchange or the Convertible Debenture Exchange and any fraction will be rounded down to the nearest whole number of common shares. Just Energy has reached an agreement in principle to settle litigation related to the 2018 acquisition of Filter Group Inc., with the resulting release of any claims. Under the terms of the proposed settlement, shareholders of the Filter Group will receive an aggregate of $1.8 million in cash and 429,958 shares, issued upon implementation of the Recapitalization.

09:03 EDT Vendorly signs reseller agreement with Secure Insight - Vendorly announced it signed a reseller agreement with risk management company Secure Insight to help protect Vendorly clients against wire fraud, a key risk to the lending and banking industries. This alliance furthers Vendorly's offering of a cradle-to-grave solution for the lending and banking industries that helps mitigate ongoing risks associated with vendor management. The Vendorly platform is a third-party risk management solution designed to help streamline vendor due diligence, maintain vendor documentation, and maintain, monitor and audit vendors. Vendorly has provided oversight of over 60,000 vendors in the lending and banking industries. Because a one-size-fits-all approach to recurring due diligence questionnaires is not always applicable, Vendorly offers customized levels of questionnaires and research specific to nearly every vendor type in the lending and banking industries. Vendorly provides the tools and expertise its clients need to help efficiently manage their TPRM obligations. Now, by working with Secure Insight, Vendorly also helps safeguard against wire fraud.

09:02 EDT OrthoPediatrics announces 1,000th procedure utilizing PNP FEMUR system - OrthoPediatrics announced completion of the 1,000th surgery utilizing its Pediatric Nailing Platform FEMUR, the first system specifically designed and developed to address the unique pediatric anatomies when treating femoral fractures and deformity correction procedures. PNP FEMUR, which received FDA 510(k) clearance in 2018, is an intramedullary nailing system to stabilize fractures and deformity correction osteotomies. It features a full suite of innovative instrumentation offering two distinct child and adolescent implant options optimized to handle the unique needs of small stature trauma and deformity procedures. The system's enhanced child sized nails range from 7-9mm and the new adolescent sized nails range from 9-12mm. The PNP system offers the widest range of nail and screw options coupled with unique size specific nail features implanted through proprietary instrumentation; providing a full spectrum, all-inclusive system to treat children of any age and size.

08:57 EDT Criteo appoints Sarah Glickman as CFO - Criteo (CRTO) announced the appointment of Sarah Glickman as CFO, effective September 8. She will serve as both Criteo's principal financial officer and principal accounting officer, and will replace Dave Anderson, who served as interim CFO for four months. Glickman most recently served as Acting CFO for 20 months at XPO Logistics (XPO).

08:54 EDT Ciena CFO sees restrained customer spending persisting 'a few quarters' - Ciena CFO James Moylan said during the company's Q3 earnings call that looking beyond Q4, based on what the company sees today and with limited visibility, he expects current market dynamics, "in particular, the challenges around restrained customer spending as well as business velocity, will persist for a few quarters." However, "as a result of our fundamental strengths, we have the unique capability to continue investing in our business, in our people, in our products and in our customers, with a focus on managing the business for the long-term and continued market leadership," said Moylan, who added that Ciena expects, "even during this time of lower revenue, to generate strong gross margins and profitability." Ciena shares are down $29.28, or 6.5%, to $418.09 in pre-market trading as the company's earnings call Q&A continues.

08:47 EDT Jaguar Health launches mental health Entheogen Therapeutics Initiative - Jaguar Health announced the launch of its mental health Entheogen Therapeutics Initiative that aims to discover and develop natural medicines derived from psychoactive plants for treatment of mood disorders, neuro-degenerative diseases, addiction, and other mental health disorders. The initiative will initially focus on plants from the company's proprietary library of 2,300 plants, with the objective of identifying plants that may have the potential to treat mood disorders, including depression. Jaguar is in the process of engaging medicinal tropical scientific strategy team advisors and intends to seek corporate partnerships.

08:45 EDT Ciena saw greater than expected COVID impacts late in Q3 - Ciena CEO Gary Smith, speaking on the company's earnings call, said "we began to experience a meaningful slowdown in orders and a softening of our outlook [late in the fiscal third quarter]. I would stress that the decline is broad-based across our service provider customers globally, whose spend now appears to have been somewhat front-end loaded in the calendar year, resulting in lower orders in our third quarter from a number of our large customers in this segment." Smith added that " in fiscal 2020, as expected, one of our large webscale customers reduced its optical spend as it had some absorption and changes to its architecture. While I would stress that we've gained share, significant share with others, including a new significant architectural win with one of the major players that is new to Ciena, we now believe that overall optical spend growth in this webscale segment will be flat to low single digits for this year versus the 7% to 10% that was expected at the beginning of the year. And I would stress that our competitive position remains strong in this key vertical, and we remain confident that we have gained share in all of the other accounts... As a result of the broader economic conditions and related market dynamics, we now expect overall market optical growth, excluding China, will slow. In fact, we now believe that the market will be roughly flat to down for this year. And this dynamic has already been reflected in some of the latest industry analyst forecast, and we expect that sentiment to continue."

08:40 EDT Duluth Holdings 'unable to provide' earnings guidance - Given the unpredictability of the effects of the COVID-19 pandemic on, among other things, consumer behavior, store traffic, store operations, production capabilities, timing of deliveries, our people, economic activity and the market generally in the coming weeks and months, the Company is unable to provide specific earnings guidance at this time. In response to expected impacts to sales plans, the Company has reduced its planned capital spend levels from the beginning of the fiscal year by 50% to approximately $15M primarily by decreasing fiscal 2020 new store openings to four and deferring certain technology and infrastructure projects, as well as continuing to focus on managing expense, extending payment terms and adjusting inventory receipt plans.

08:36 EDT 89bio initiates Phase 2 trial of BIO89-100 in severe hypertriglyceridemia - 89bio announced the initiation of a Phase 2 trial evaluating its product candidate BIO89-100 in patients with severe hypertriglyceridemia. BIO89-100 is a glycoPEGylated analog of fibroblast growth factor 21 in clinical development for the treatment of nonalcoholic steatohepatitis and SHTG. The Phase 2 trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the safety, efficacy, and tolerability of BIO89-100 in patients with SHTG. The study will enroll approximately 90 patients who will be treated with BIO89-100 in one of four treatment groups or placebo administered in either weekly or every two weeks doses for a period of 8 weeks. The primary endpoint is the reduction in fasting triglycerides from baseline. Key secondary endpoints include the effect of BIO89-100 on other lipids and metabolic markers and change in liver fat measured by magnetic resonance imaging proton density fat fraction. Patients who meet screening criteria will undergo a lifestyle stabilization and triglyceride qualification period prior to randomization and will receive lifestyle counseling during the study.

08:35 EDT VistaGen Therapeutics reports 'positive' data in new preclinical AV-101 study - VistaGen Therapeutics announced positive new data from the company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results of this new study complement previous preclinical data demonstrating the combination's potential to increase the brain concentration of AV-101's active metabolite, 7-Cl-KYN, a selective full antagonist of the NMDA receptor glycine co-agonist site, thereby reducing, rather than blocking, NMDA receptor signaling. The second preclinical pharmacokinetic study of AV-101 and probenecid involved four groups. A single oral gavage administration of AV-101 at both dose levels alone or in combination with intravenous probenecid was well-tolerated. CSF levels of both AV-101 and 7-Cl-KYNA increased roughly dose proportionally. AV-101 administered with probenecid increased the CSF 7-Cl-KYNA AUC - total drug exposure across time - by approximately 4.6 times, compared to AV-101 alone. The AV-101-probenecid combination appeared safe and well-tolerated. The FDA has granted Fast Track designation for development of AV-101 as both a potential adjunctive treatment for major depressive disorder and as a non-opioid treatment for neuropathic pain.

08:21 EDT GM, Honda sign MoU toward establishing strategic alliance in North America - General Motors and Honda announced they have signed a non-binding memorandum of understanding following extensive preliminary discussions toward establishing a North American automotive alliance. The companies said in a release, "The scope of the proposed alliance includes a range of vehicles to be sold under each company's distinct brands, as well as cooperation in purchasing, research and development, and connected services. Under the proposed alliance, Honda and GM would collaborate on a variety of segments in North America, intending to share common vehicle platforms, including both electrified and internal combustion propulsion systems that align with the vehicle platforms. Co-development planning discussions will begin immediately, with engineering work beginning in early 2021. The announcement builds on the agreement signed between the companies in April to jointly develop two all-new electric vehicles for Honda based on GM's highly flexible global EV platform powered by Ultium batteries. The GM-Honda relationship, which began more than two decades ago, includes recent collaboration between the companies on fuel cells, batteries and the Cruise Origin shared autonomous vehicle. An alliance in North America between Honda and GM would leverage the best technologies and generate substantial cost efficiencies from shared vehicle platforms and propulsion systems, joint purchasing, potential manufacturing efficiencies and other collaboration efforts. This would enable both GM and Honda to make greater investments in advanced and next-generation technologies. GM and Honda also plan to share R&D and engineering costs for select future co-developed vehicle and propulsion platforms. This would create substantial efficiencies and free up capital, enabling both companies to meet the increasing requirements to invest in various future mobility trends and additional growth opportunities for each company's distinct brands. Honda and GM plan to collaborate in joint purchasing activities to create further cost efficiencies by leveraging both companies' respective scale, insight and best practices. Purchasing collaboration would be focused on joint sourcing of materials, logistics and localization strategies. All facets of the alliance will be governed by a joint committee, comprising senior executives from both companies."

08:18 EDT DZS teams with Nimbus Networks for hyper-connectivity, contactless solutions - DZS has partnered with Nimbus Networks to deliver a cutting-edge hyper-connected experience to over 20 high-end hotels across Latin America. By leveraging DZS FiberLAN technology, a state-of-the-art fiber optic and Wi-Fi infrastructure, and unique applications like Nimbus unique cloud based services, these hotels are revolutionizing the hospitality industry by raising the bar on customer expectations when they stay at Nimbus-enabled hotels. The DZS FiberLAN solutions leveraged by Nimbus utilize multi-gigabit capable GPON technology on the MXK-F OLT and Z-Series ONTs and wireless access points featuring world-class Wi-Fi technology. Across this infrastructure, many of the hotels served by DZS and Nimbus have deployed Nimbus Contactless Cloud applications which allow hotel guests to leverage their own personal mobile phone to create a new hotel experience. First thought of as "healthy building" technology, Contactless Cloud is turning out to be a perfect product for the COVID-19 pandemic.

08:17 EDT Proofpoint, CyberArk extend partnership to further safeguard high-risk users - Proofpoint announced it is extending its partnership with CyberArk, the global leader in privileged access management. The enhanced integration of Proofpoint Targeted Attack Protection with CyberArk's Privileged Access Security Solution enables organizations to identify their very attacked people, apply additional security policies to their high-risk users with privileged access, and remediate phishing attempts. The Proofpoint and CyberArk partnership features a combination of layered defenses designed to stop threats before they reach users and apply policies and controls that ensure privilege accuracy. Proofpoint prevents email attacks from accessing users and helps to identify the individuals that are targeted by the most sophisticated, highest impact threats. CyberArk takes this insight and applies adaptive controls and policies to ensure those privileged users are only able to access what they need and nothing more.

08:16 EDT Jack Henry's digital lending platform adopted by Guilford Savings Bank - Jack Henry announced that Connecticut-based Guilford Savings Bank has launched the Commercial Lending Center Suite to streamline the commercial lending process, automating previously manual tasks. This implementation follows the bank's conversion to Jack Henry for core and digital banking. Guilford Savings Bank's previous loan origination system was largely manual. The bank leveraged Jack Henry's Paycheck Protection Program lending solution to help businesses.

08:15 EDT Verastem pre-print article published by bioRxiv - A pre-print article entitled "Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells" was published by bioRxiv, which notes on its site that it "is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information."

08:14 EDT CNS Pharmaceuticals announces U.S. drug manufacturing milestones - CNS Pharmaceuticals provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and engaged U.S.-based Pharmaceutics International, and Italy-based BSP Pharmaceuticals S.p.A. for the production of Berubicin. By engaging two separate manufacturers on two separate continents, CNS expects to mitigate COVID-19-related delay risks, diversify its supply chain and provide for localized availability of Berubicin. Under this dual-track strategy, the Company has achieved several key milestones in its manufacturing efforts and is providing an update on the progress made with its U.S. manufacturer, Pii. First, CNS completed synthesis of Berubicin active pharmaceutical ingredient and shipped API to both manufacturers to prepare an injectable form of Berubicin for clinical use. In preparation for production, CNS and Pii have now agreed on the manufacturing procedure and packaging components for Berubicin and selected a sterile filter manufacturer. The Company has also completed and reviewed a draft of the batch record. Importantly, the Company and Pii completed a successful laboratory simulation of the lyophilization cycle. The Company expects to begin manufacturing of Berubicin at Pii during the third quarter of this year. CNS's preparations for filing an IND entail both extensive clinical and manufacturing initiatives. In addition to the progress the Company has made in its manufacturing efforts, it has recently announced critical achievements made on the clinical front. The Company engaged Worldwide Clinical Trials as the contract research organization for its upcoming Berubicin clinical trials. Worldwide specializes in therapeutic areas with unmet medical needs, including CNS disorders and oncology. Worldwide will work closely with CNS to provide proactive insight and operational support for its upcoming trials. Additionally, the Company engaged Berry Consultants, a leading clinical statistical consulting group, to advise on its Phase 2 trial design for Berubicin. Berry Consultants uses Bayesian statistics to provide innovative clinical trial designs and analysis. The Company has also completed the Phase 1 Clinical Study Report, or CSR, which is now ready for publication. CNS was recently granted Orphan Drug Designation for its lead product, Berubicin, for the treatment of malignant gliomas. The designation provides Berubicin with a special status that can help accelerate its development to treat malignant gliomas by providing CNS with the potential for market exclusivity upon the drug's approval. The Company plans to file an IND for Berubicin with the FDA during the fourth quarter of 2020.

08:12 EDT Cancer Genetics, StemoniX announce joint PoC program - Cancer Genetics and StemoniX announced a joint proof-of-concept program. StemoniX and vivoPharm, a subsidiary of Cancer Genetics, recently launched a joint proof-of-concept program to assess CNS safety and toxicity of novel compounds. The Companies believe that combining capabilities and technologies from each team will save time, drive cost efficiency, and de-risk decisions, thereby establishing higher confidence in drug development success. The parties anticipate that the alliance will demonstrate the expertise of each company and be a first step for continuing to push forward and develop cutting edge drug discovery efforts. Cancer Genetics and StemoniX will look to pursue follow-on projects to further demonstrate how a combined approach brings high value to clients in the form of a complete end-to-end solution.

08:11 EDT VirTra receives $863,000 order from Customs and Border Protection - VirTra has received an order from the U.S. Customs and Border Protection for simulation training products and services, including new, drop-in recoil kits, valued at $863,000. The order from CBP is part of an existing indefinite delivery/indefinite quantity contract from the U.S. Department of Homeland Security. The IDIQ contract, which VirTra originally received in 2016, had a one-year base term with four additional option years and a potential value of up to $9.0 million. To date, CBP has purchased approximately $5.2 million of products and services from VirTra through this vehicle. VirTra anticipates recognizing revenues from this new $863,000 delivery order before the end of 2020.

08:09 EDT OncoCyte, the Guardian Research Network announce strategic alliance - Oncocyte and the Guardian Research Network announced a strategic collaboration to create a comprehensive solution for pharma clients from patient recruitment to regulatory approvals. Oncocyte and GRN aim to leverage their joint capabilities by bringing together GRN's clinical trial enrollment and data science technology with Oncocyte's proprietary molecular tests, including DetermaRx for early stage lung cancer and DetermaIO for immunotherapy selection, as well as Oncocyte's pharma and companion diagnostic development services. The collaboration is designed to reduce the time to populate immune targeting trials while also improving chances for successful trials through proprietary molecular patient stratification.

08:07 EDT Kratos Defense launches OpenSpace Wideband Software Reciever - Kratos Defense & Security Solutions announced the launch of its OpenSpace Wideband Software Receiver supporting the high data rates, scalability and interoperability needs of today's Earth Observation and Remote Sensing missions. As more and more data is being beamed from satellites, the infrastructure on the ground must become highly flexible and more cost-effective to address the key challenge of EO applications - the need to rapidly download data on the fly during the short time periods when satellites are over the ground station. Kratos' OpenSpace Wideband Software Receiver is the only completely virtual receiver with no Field Programmable Gate Array or Graphics Processing Unit. The software receiver takes advantage of virtual and cloud-based architectures and runs on standard x86 servers. The OpenSpace Wideband Software Receiver offers 600 Mbps of throughput to support downlinks across several hundred MHz of instantaneous bandwidth, an unmatched level of signal processing in software. The performance of the OpenSpace Wideband Software Receiver is equivalent to hardware based EO and remote sensing receivers in the market. Unlike traditional EO and remote sensing hardware that is proprietary and purpose built, the software-only receiver easily scales based on demand and embraces open standards including VITA 49 and CCSDS.

08:04 EDT Kite, HiFiBiO Therapeutics announce two-year research collaboration in AML - Kite, a Gilead company, and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia, or AML. Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite's use in cell therapies. Under the terms of the agreement, HiFiBiO will receive an upfront payment and will be eligible for additional payments based on the achievement of certain research milestones. Kite will have an exclusive option to opt in on any targets discovered through the collaboration, for which HiFiBiO will receive an additional payment and will be eligible for additional development, regulatory and commercial milestone payments, as well as royalty payments.

07:49 EDT Samsung Biologics plans $2B 'Super Plant' amid biologic drug demand, WSJ says - Samsung Biologics is betting that the market for biologic drug ingredients will continue to grow with a roughly $2B drugmaking plant to be completed in 2022, the Wall Street Journal's Elizabeth Koh reports, citing CEO Kim Tae-Han. The factory, dubbed the "Super Plant", is Samsung Biologics' fourth plant and will have about 230,000 square meters of floor space making it the bigger than the company's three current plants combined and slightly larger than the Louvre. Reference Link

07:37 EDT Crinetics appoints Camille Bedrosian to board of directors - Crinetics Pharmaceuticals (CRNX) announced the appointment of Camille Bedrosian, M.D. as an independent member of its board of directors. Dr. Bedrosian currently serves as EVP and CMO of Ultragenyx Pharmaceutical (RARE).

07:35 EDT Tradeweb Markets reports ADV of $747.1B in August, down 9.9% - Tradeweb Markets reported total August trading volume of $15.7T. Average daily volume, or ADV, was $747.1B in August, a decrease of 9.9% year-over-year.

07:33 EDT Dollar Tree announces opening of 25th, 26th distribution centers - Dollar Tree announced the opening of its 25th U.S. distribution center in Rosenberg, Texas. The company also recently started shipping product from its 26th U.S. facility in Ocala, Florida. The plans for the approximate $130M investment in the Texas distribution center were announced in February 2019. The 1.2m square foot facility will initially service Dollar Tree stores across a three state region. To continue supporting its stores, the company recently began shipping product from its Ocala, Florida distribution center. The first phase of the 1.2m square foot facility opened last month, with the second phase expected to be completed in 2022.

07:31 EDT Primoris announces pipeline award valued over $75M - Primoris Services announced three new pipeline awards with a combined value over $75M. The contracts were secured by the Pipeline & Underground segment. The awards are for the installation of over thirty miles of various diameter pipeline in Texas. Work is scheduled to commence in the third quarter of 2020, and completion is expected in the second quarter of 2021.

07:24 EDT Taylor Morrison reports August net sales orders up 74% year-over-year - Taylor Morrison announced its August net sales orders performance and a cash paydown of approximately $187M of senior notes. Following its Q2 performance, which included the company's best sales month on record, Taylor Morrison finished August with net sales orders up 74% year-over-year. Average sales pace per community for August was up more than 50% year-over-year.

07:19 EDT Green Thumb Industries announces LEAP new business accelerator - Green Thumb Industries announced the launch of the LEAP New Business Accelerator, a cannabis business incubator intended to help promote opportunity and success for new social equity entrepreneurs in the nascent cannabis industry. The program follows Green Thumb's License Education Assistance Program, a pro-bono program where the Company's license application team mentored hundreds of social equity applicants in their pursuit of licenses to be issued as part of the Illinois adult use program. The LEAP New Business Accelerator will launch in Illinois following the State of Illinois' announcement of new social equity dispensary licensees expected later this month. The LEAP New Business Accelerator will offer intensive in-house mentorship to two to three dispensary licensees and one to two craft grower licensees as the program shifts its focus to position new cannabis businesses for success. Upon social equity licenses being awarded by the Department of Financial and Professional Regulation, Green Thumb will open an application period in which dispensary licensees can apply for the incubator program. Green Thumb will open a similar incubator application period following the award of craft grower licenses to social equity applicants by the Department of Agriculture.

07:16 EDT Old Dominion provides LTL operating metrics for August - Old Dominion reported certain less-than-truckload, or LTL, operating metrics for August. Revenue per day increased 1.3% as compared to August 2019 due to a 2.4% increase in LTL tons per day that was partially offset by a decrease in LTL revenue per hundredweight. The change in LTL tons per day was attributable to a 5.9% increase in LTL weight per shipment that was partially offset by a 3.3% decrease in LTL shipments per day. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight excluding fuel surcharges decreased 0.9% and increased 2.3%, respectively, as compared to the same period last year.

07:14 EDT Sol-Gel partner files first-to-file Paragraph IV Certification for Duobrii - Sol-Gel Technologies (SLGL) announced that Bausch Health Companies (BHC) initiated patent infringement action in the U.S. District Court for the District of New Jersey on August 31, 2020 with regards to Perrigo Company (PRGO) Abbreviated New Drug Application for a generic version of Duobrii lotion, for the treatment of plaque psoriasis in adults. On July 23, 2020, Sol-Gel's partner Perrigo filed a Notice of first-to-file Paragraph IV Certification asserting that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo's generic lotion. Development of halobetasol propionate and tazarotene lotion is covered under a previous collaboration between Sol-Gel and Perrigo. Consistent with Sol-Gel's prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration for the generic product candidate. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidate in the United States. Sol-Gel and Perrigo will share the development costs and any gross profits generated from potential sales of the generic product candidate. Annual market sales of Duobrii for the last 12 months ended July 2020 amounted to $88.4M.

07:10 EDT U.S. government exercises option to purchase additional RAPIVAB from BioCryst - BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services has exercised its option to purchase an additional 10,000 doses of BioCryst's approved antiviral influenza therapy, RAPIVAB, for approximately $7M. The RAPIVAB purchase by the HHS Office of the Assistant Secretary for Preparedness and Response will supply the Strategic National Stockpile, the nation's largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency. The order is part of a $34.7M contract the Centers for Disease Control and Prevention awarded in 2018 for the procurement of up to 50,000 doses of RAPIVAB over a five-year period for the SNS.

07:09 EDT Altair extends strategic OEM agreement with Hewlett Packard Enterprise - Altair (ALTR) extended its multi-year OEM agreement with Hewlett Packard Enterprise (HPE) to offer the newly enhanced version of Altair PBS Professional workload manager and job scheduler across HPE's industry-leading HPC systems, including HPE Apollo Systems and new line of HPE Cray supercomputers. HPE Pointnext Technology Services, which provides advisory and professional services to design and deploy solutions, will also be used to offer support for Altair's latest software offering. Key enhancements include massive improvements in throughput, support for both high performance and high-throughput workloads, effortless access to on-demand cloud resources, and new freedom to control and optimize budgets throughout an organization.

07:06 EDT Avanos' Coolief shows superior efficacy over injections for chronic knee pain - Avanos Medical announced the publication of a large, randomized, multicentered clinical trial comparing the safety and efficacy of Coolief Cooled Radiofrequency ablation to hyaluronic acid injection for the management of chronic knee pain caused by osteoarthritis. The results from the clinical trial were published in the Journal of Bone & Joint Surgery, the official journal of the American Orthopedic Association. Existing treatments for knee osteoarthritis consist of short-lasting and often repetitive nonsurgical options, followed by surgical intervention for those who are appropriate candidates. Coolief Cooled RF is an FDA cleared minimally invasive procedure in the management of knee OA pain. At the 6-month timepoint, 71.1% of subjects receiving CRFA reported greater than or equal to 50% pain relief compared to 37.8% of subjects receiving HA. Those receiving CRFA had a 48.2% improvement in WOMAC score at 6 months, compared to 22.6% of subjects treated with HA. Additionally, 72.4% of subjects in the CRFA group reported improvements in GPE compared to 40.2% in the HA group. The 12-month, 18-month and 24-month timepoints will be reported in future publications.

07:03 EDT BeyondSpring announces anticipated milestones - The following outlines the Company's anticipated upcoming milestones and projected timelines: Final data readout for PROTECTIVE-2 Phase 3 for CIN - Q4 2020; NDA submission for Plinabulin for CIN in the U.S. - end of 2020; Final topline data readout for DUBLIN-3 for NSCLC - H1 2021; Rolling NDA submission for Plinabulin for NSCLC in China - H1 2021; NDA submission for Plinabulin for NSCLC in the U.S. - H2 2021.

06:57 EDT Tyson Foods enters partnership with Marathon Health to pilot 7 health clinics - Tyson Foods said in a release, "As part of efforts to boost the overall health and wellness of its workforce, Tyson Foods is partnering with Marathon Health to pilot seven health clinics near company production facilities. The clinics will give Tyson team members and their families easier access to high-quality healthcare and, in most cases, at no cost. The clinics, which will be operated by Marathon Health, will provide primary and preventive care, including health screenings, lifestyle coaching and health education, as well as behavioral health counseling. They will also collaborate with plant community health providers, including primary care physicians and specialists, to ensure appropriate care is delivered. The pilot clinic project represents the expansion of the company's We Care workplace safety program to include overall team member health and wellness. It is an addition to the company's existing health services staff, which includes on-site occupational health nurses at most plant locations. One of the first clinics will be in Storm Lake, Iowa, where the company operates two plants and employs more than 3,300 people. A clinic will also be established at the company's Holcomb, Kansas, plant that employs more than 3,000 people. The locations of the other clinics will be disclosed soon. Marathon Health is targeting to start opening centers in the first half of 2021. The seven pilot clinics will serve nearly 38,000 Tyson team members and their families. Spouses, dependents age 2 and older who are covered by the Tyson insurance plan, will be eligible. The clinics will be designed to serve a diverse workforce, providing communications in multiple languages."

06:52 EDT The Buckle reports August SSS up 1.7% - The Buckle said in a release, "The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended August 29, 2020 increased 1.7 percent from comparable store net sales for the 4-week period ended August 31, 2019. Net sales for the 4-week fiscal month ended August 29, 2020 increased 1.2 percent to $78.1 million from net sales of $77.2 million for the prior year 4-week fiscal month ended August 31, 2019. As of August 29, 2020, 432 of Buckle's 446 stores were open. Of the 14 stores which were closed, 1 has not yet reopened due to damage sustained during the COVID-19 closure period. The remaining 13 stores are located in California and had previously reopened but were subsequently closed again in accordance with state guidelines. Comparable store net sales, excluding these 14 closed stores, for the 4-week period ended August 29, 2020 increased 4.6 percent from comparable store net sales for the same period a year ago."

06:43 EDT Babcock & Wilcox announces board changes - Babcock & Wilcox said in a release, "Babcock & Wilcox Enterprises announced the appointment of three new independent members to its board, reflecting a well-planned transition and strategic shift to accelerate growth within B&W in light of improved operational stability. The new independent members are Philip Moeller, Rebecca Stahl and Joseph Tato. CEO Kenneth Young and Chief Strategy Officer Henry Bartoli have also joined the Board, with Young appointed as Chairman of the Board. In connection with this transition, Matthew Avril (former Chairman), Cynthia Dubin, Brian Kahn, Bryant Riley and Kenneth Siegel have retired from the Board. As a result of the transition, the new board is comprised of six members, with four serving as independent directors, including current Director Alan Howe becoming Lead Independent Director. In order to provide continuity, the retiring Board members will be available to provide support to the new board through the end of the year."

06:40 EDT Centogene publishes dataset that supports genome sequencing as diagnosis - Centogene's scientific publication has appeared in the European Journal of Human Genetics, the official journal of the European Society of Human Genetics. The study presents one of the largest cohorts of patients with genome sequencing performed in a clinical setting to date and suggests GS as a first-line test for diagnosing rare disease patients. The paper finds that GS was especially valuable for patients who had received a negative diagnostic report from previous exome sequencing, and relates this observation to the technological superiority of GS. It concludes that the use of GS as a comprehensive first-line genetic test would avoid the diagnostic delay and potentially higher financial burden associated with stepwise testing.

06:35 EDT Quarterhill subsidiary awarded contract for two WIM systems in Paraguay - International Road Dynamics, a Quarterhill company, announced that PAT Traffic, a wholly owned subsidiary of IRD, has received a contract for the design, supply, installation and service, and the integration of two weigh-in-motion, or WIM, systems in the Republic of Paraguay. The stations are located on a bypass highway near Asuncion along a truck route to a local transfer station. The stations provide commercial vehicle enforcement solutions integrating WIM systems with complementary technologies such as real-time vehicle dimensioning systems and axle load and gross vehicle weight information. This is a continuation of a country wide truck compliance program utilizing IRD-PAT systems to improve truck transport efficiency while protecting the highway infrastructure.

06:23 EDT Kronos Advanced Technologies enters pilot distribution agreement with SteriLED - Kronos Advanced Technologies announced it has entered into a pilot distribution agreement with SteriLED, a division of Principal Lighting Group. SteriLED has agreed to supply Kronos with its commercial-grade ultraviolet germicidal irradiation product line that was laboratory tested to effectively disinfect objects and surfaces without the need for consumable cleaning agents. These products utilize proprietary UVC semiconductor diodes to output a high-power, 275nm ultraviolet light that inactivates the DNA and RNA of microorganisms like mold, bacteria and viruses. The SteriLED devices are lightweight and only take seconds to disinfect almost any object. When incorporated to be used with Kronos air purification products, which are commonly installed in homes and spaces such as offices, classrooms, restaurants, retail stores and other public facilities, the SteriLED's specially designed LED module will emit the 275nm UV light to inactivate pathogens on surfaces. Based on advanced research and technology, the UV light SteriLED product has reportedly been tested by Harvard Medical School and Boston University. Kronos expects to introduce new SteriLED handheld UV sterilisation products to its customers in September.

06:03 EDT General Moly enters into LOI to sell Liberty Project to Pathfinder Minerals - General Moly said in a release, "General Moly announced that on September 1, 2020, it entered into a binding letter of intent, or LOI, with Pathfinder Minerals a Nevada corporation, for the sale by the Company of Liberty Moly and all assets owned by the Company that constitute the Liberty Project. Pathfinder paid the Company $1M in cash upon execution of the letter of intent. Upon execution of a definitive Purchase Agreement and transfer of title on or before September 15, Pathfinder will make an additional payment of $1M to the Company. A further $1M will be payable on completion of commissioning of a production plant of any metal commodity on the property. The Company will retain a 3% net smelter return royalty on molybdenum production from the property. Notwithstanding this transaction, the Company still has a significant working capital deficit and there remains substantial doubt about the Company's ability to continue as a going concern. If the Company is unable to find an additional source of funding, it will be forced to cease operations and pursue restructuring or liquidation alternatives, including the filing for bankruptcy protection, in which event the Company's common stock would likely become worthless and investors would likely lose their entire investment in the Company. In addition, holders of the Company's outstanding convertible preferred stock and senior notes would likely receive significantly less than the principal amount of their claims and possibly, no recovery at all. As of the date of this news release, the Company has no commitments for additional funding and there can be no assurance that the Company will be successful in obtaining the financing required to complete the Mt. Hope Project, or in raising additional financing in the future on terms acceptable to the Company, or at all."

06:00 EDT Farmmi receives seventh follow-on order from existing customer - Farmmi said in a release, "Farmmi announced its subsidiary Zhejiang Forest Food Co., Ltd., has received its seventh follow-on order from the same existing customer. The latest order is for dried Shiitake mushrooms, dried and sliced Shiitake mushrooms and dried black Mu Er. The customer, an Israeli import and marketing company, will export the mushrooms to Israel."

05:28 EDT Chi-Med initiates Phase II study of HMPL-453 - Hutchison China MediTech said in a release, "Chi-Med has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors, or FGFR, in patients with advanced intrahepatic cholangiocarcinoma, or IHCC, which is a type of liver cancer. The clinical study is a single-arm, multi-center, open-label study, evaluating the efficacy, safety and pharmacokinetics of HMPL-453 in patients with advanced IHCC with FGFR2 fusion that had failed at least one line of systemic therapy. The primary outcome measure is objective response rate, or ORR. Secondary outcome evaluations include preliminary efficacy measures, such as disease control rate, or DCR, time to response, or TTR, duration of response, or DoR, progression-free survival, or PFS, and overall survival, or OS. Additional details may be found at clinicaltrials.gov, using identifier NCT04353375."